However, further support is provided by observations that TNFR2+ CD26− cells of patients were more susceptible than those healthy controls, and that those of naive patients were more susceptible than those of treated patients, since all treatments for SS aim to slow down the proliferation of neoplastic lymphocytes. The gene discussed is TNFRSF1B; the disease is synovial sarcoma.